Evidence map›Paper›PMID 36982170›Full record

ArticleInternational journal of molecular sciences2023

A

Wei Jiang, Xueyan Ouyang, Chunjuan Jiang, Lina Yin, Qianlan Yao, Xuan Pei, Zhaodong Ji, Ming Li, Shaoli Song, Wentao Yang and 3 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Wei JiangDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Xueyan OuyangDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Chunjuan JiangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Lina YinDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Qianlan YaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xuan PeiDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Zhaodong JiDepartment of Clinical Laboratory, Huashan Hospital, Fudan University, Shanghai 200040, China.
Ming LiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.ORCID 0000-0002-0063-9715
Shaoli SongDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.ORCID 0000-0003-2544-7522
Wentao YangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Shenglin HuangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Huijuan YangDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Boer ShanDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Shanghai Medical College of Fudan University · CNFudan University · CN

Funding

National Natural Science Young Foundation of China 81802594Shanghai Natural Science Foundation of China 20ZR1413000Shanghai Shenkang Research and Development Center SHDC2020CR3059
6 · The paper itself

Abstract

Peritoneal implantation and lymph node metastasis have different driving mechanisms in ovarian cancer. Elucidating the underlying mechanism of lymph node metastasis is important for treatment outcomes. A new cell line, FDOVL, was established from a metastatic lymph node of a patient with primary platinum-resistant ovarian cancer and was then characterized. The effect of

Indexed as

Ovarian NeoplasmsAnimalsCarcinoma, Ovarian EpithelialCell LineFemaleHumansLymphatic MetastasisLymph NodesMutationReceptor, Notch1NOTCH1 protein, humanReceptor, Notch1newly established ovarian cancer cell line (FDOVL)NOTCH1-p.C702fs mutationovarian cancerperitoneal and lymph node metastasis

Identifiers

PMID36982170
PMCPMC10049685
OpenAlexW4323566534

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read42
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.